[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369081-105":59,"doc-detail-369081-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","therapeutic-expression-of-ras-degrader-rrsp-in-pancreatic-cancer-via-nanocarrier-mediated-mrna-delivery","Therapeutic expression of RAS Degrader RRSP in Pancreatic Cancer via Nanocarrier-mediated mRNA delivery","","About one-third of human cancers encode abnormal RAS proteins locked in a constitutively activated state, driving malignant transformation and uncontrolled tumor growth. Even with advances in small-molecule treatments for mutant KRAS cancers, an effective pan-RAS inhibitor that works across isoforms and variants while limiting drug resistance remains needed. This study develops in vivo expression of the RAS degrader RRSP using synthetic nonviral mRNA delivery with PEG-b-PPS and PPDP2, yielding RRSP gene expression and tumor reduction in pancreatic models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-expression-of-ras-degrader-rrsp-in-pancreatic-cancer-via-nanocarrier-mediated-mrna-delivery/369081/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-expression-of-ras-degrader-rrsp-in-pancreatic-cancer-via-nanocarrier-mediated-mrna-delivery/369081.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the therapeutic approach described for targeting RAS in pancreatic cancer?","Question",{"text":112,"@type":113},"The study uses synthetic nanocarriers to deliver mRNA that induces expression of the RAS degrader enzyme RRSP inside cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What nanocarrier platform delivers the RRSP mRNA?",{"text":117,"@type":113},"The nonviral system combines the PEG-b-PPS block copolymer conjugated to a dendritic cationic peptide (PPDP2).",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes are reported after mRNA delivery in pancreatic models?",{"text":121,"@type":113},"RRSP gene expression and activity lead to loss of cell proliferation, and pancreatic tumors are reduced with residual tumors lacking detectable RAS and phosphorylated ERK.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369081,1790862946,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":36,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","bioRxiv preprint doi: [https://doi.org/10.1101/2024.06.11.598439](https://doi.org/10.1101/2024.06.11.598439); this version posted June 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-NC 4.0 International license.  \n1  \n1 Therapeutic expression of RAS Degrader RRSP in Pancreatic Cancer via  \n2 Nanocarrier-mediated mRNA delivery  \n3 Taylor E. Escher,1 Simseok A. Yuk,2 Yuan Qian,2 Caleb K. Stubbs,1 Evan A. Scott,2,3,4,5 and  \n4 Karla J. F. Satchell1,5  \n5  \n6 1 Department of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, 7 Chicago, IL 60611 United States  \n8 2 Department of Biomedical Engineering, Northwestern University, Evanston, IL 60208, USA.  \n9 3Simpson Querrey Institute, Northwestern University, Chicago, IL 60611, USA.  \n10 4Chemistry of Life Processes Institute, Northwestern University, Evanston, IL 60208, USA.  \n11 5 Robert H. Lurie Comprehensive Cancer Research Center, Northwestern University, Feinberg  \n12 School of Medicine, Chicago, IL 60611 United States 13  \n14 Correspondence should be addressed to:  \n15 Karla J. F. Satchell: Northwestern University, Feinberg School of Medicine, Chicago, Illinois, 16 60611, United States. Email: [k-satchell@northwestern.edu](k-satchell@northwestern.edu); Ph: 312-503-2162  \n17 Short title: Nanocarrier delivery of mRNA for RAS degrader  \n18 Keywords: RRSP, nanocarriers, RAS, degrader  \n19  \n20  \n21 Graphical Abstract: Synthetic nanocarriers packaged with mRNA are used to express the  \n22 RAS-specific protease RRSP in cancer cells resulting in cell death and tumor shrinkage.  \nbioRxiv preprint doi: [https://doi.org/10.1101/2024.06.11.598439](https://doi.org/10.1101/2024.06.11.598439); this version posted June 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made  \navailable under aCC-BY-NC 4.0 International license.  \n2  \n23 ABSTRACT  \n24 About one-third of all human cancers encode abnormal RAS proteins locked in a constitutively  \n25 activated state to drive malignant transformation and uncontrolled tumor growth. Despite progress  \n26 in development of small molecules for treatment of mutant KRAS cancers, there is a need for a  \n27 pan-RAS inhibitor that is effective against all RAS isoforms and variants and that avoids drug  \n28 resistance. We have previously shown that the naturally occurring bacterial enzyme RAS/RAP1- 29 specific endopeptidase (RRSP) is a potent RAS degrader that can be re-engineered as a biologic  \n30 therapy to induce regression of colorectal, breast, and pancreatic tumors. Here, we have  \n31 developed a strategy for in vivo expression of this RAS degrader via mRNA delivery using a  \n32 synthetic nonviral gene delivery platform composed of the poly(ethylene glycol)-b-poly(propylene  \n33 sulfide) (PEG-b-PPS) block copolymer conjugated to a dendritic cationic peptide (PPDP2) . Using  \n34 this strategy, PPDP2 is shown to deliver mRNA to both human and mouse pancreatic cells  \n35 resulting in RRSP gene expression, activity, and loss of cell proliferation. Further, pancreatic  \n36 tumors are reduced with residual tumors lacking detectable RAS and phosphorylated ERK. These  \n37 data support that mRNA-loaded synthetic nanocarrier delivery of a RAS degrader can interrupt  \n38 the RAS signaling system within pancreatic cancer cells while avoiding side effects during  \n39 therapy.  \n40 INTRODUCTION  \n41 Across all stages of pancreatic cancer, the relative survival rate for patients is only 12% . In 2024, 42 this equates to over 50,000 deaths, making it the third most deadly type of cancer in the United  \n43 States.1 Oncogenic variants of the Kirsten rat sarcoma ( KRAS) protein occur in approximately 44 95% of patients with pancreat","cbCaiiQWucE991mw","https://ap.wps.com/l/cbCaiiQWucE991mw","pdf",4135829,"English","# ABSTRACT\n# INTRODUCTION","[{\"question\":\"What is the therapeutic approach described for targeting RAS in pancreatic cancer?\",\"answer\":\"The study uses synthetic nanocarriers to deliver mRNA that induces expression of the RAS degrader enzyme RRSP inside cancer cells.\"},{\"question\":\"What nanocarrier platform delivers the RRSP mRNA?\",\"answer\":\"The nonviral system combines the PEG-b-PPS block copolymer conjugated to a dendritic cationic peptide (PPDP2).\"},{\"question\":\"What outcomes are reported after mRNA delivery in pancreatic models?\",\"answer\":\"RRSP gene expression and activity lead to loss of cell proliferation, and pancreatic tumors are reduced with residual tumors lacking detectable RAS and phosphorylated ERK.\"}]","Therapeutic expression of RAS Degrader RRSP in Pancreatic Cancer via Nanocarrier-mediated mRNA delivery | PDF",1790180595,101,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1db5d2491b29cc173fd3c80b3e1dfac0.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0129f64d1a912243ecbeac9164dedbf7.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df45172c5869a6414e45c715db03cd4e.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c42b0cccf1deff31d5a49ed24d1d3dc7.webp",980,1268]